Ontario: UCB's Prescription for Success
Location Canada 2009
In 2006, UCB Pharma Canada was established in Burlington, Ontario, to bring new and improved biopharmaceutical treatment options to Canadian patients who suffer from often-debilitating conditions. Expanding overseas was an important step for UCB in furthering its work in research and the development of treatments. To support such expansion, UCB needed greater access to a skilled work force in the life sciences, opportunities to conduct high-quality clinical trials, as well as access to partnerships with suppliers and other businesses.
The company chose Ontario as its Canadian site for several reasons, including access to reputable business partners within the Greater Toronto area; its proximity to UCB's operations in Rochester, New York; and access to skilled medical researchers. Rob Hamilton, general Manager of UCB Pharma Canada, says "A skilled work force was an important factor. We've had no problem finding people" in Ontario.
Project Announcements
Keurig Dr Pepper Canada Plans Rocky View County, Alberta, Distribution Operations
07/23/2024
Stellantis North America Establishes Brampton, Ontario, Distribution Operations
07/15/2024
Germany-Based DEKRA Plans Plymouth, Michigan, Test Center of Excellence
06/26/2024
Japan-Based Asahi Kasei Plans Port Colborne, Ontario, EV Battery Operations
05/17/2024
NewCold Plans Coaldale, Alberta, Cold Storage Operations
05/06/2024
Honda Motor Plans Alliston, Ontario, Canada, EV Production-Battery Operations
04/30/2024
Most Read
-
19th Annual Area Development Gold and Silver Shovel Awards
Q2 2024
-
What the Latest EPA PFAS Rule Means for Site Due Diligence
Q3 2024
-
Semiconductors’ fragile relationship with water may be tested
Q3 2024
-
2023 Top States Commentary: Top-Ranked States Have What It Takes to Win Mega Projects
Q3 2023
-
2023 Top States for Doing Business Meet the Needs of Site Selectors
Q3 2023
-
2023's Leading Metro Locations: Hotspots of Economic Growth
Q4 2023
-
Mitigating Site Risks for Industrial Projects
Q3 2024